With the area disinfected and prepped, youre ready to move on to preparing your medication
An epidemiologic study by Apnimed, a clinical-stage pharmaceutical company developing AD109, an oral drug candidate for OSA, demonstrated that most people with OSA60.6%are not obese
The original poster acknowledged that some might think it was because of fat loss
Overview Shed (formerly ShedRx) is a Phoenix-based telehealth platform that launched in 2022
Wegovy Just like with semaglutide, tirzepatide has two brand names: Mounjaro: FDA-approved for Type 2 Diabetes Maximum dose: 15 mg weekly Prescribed primarily for blood sugar control Zepbound: FDA-approved for weight management Same maximum dose: 15 mg weekly Marketed for obesity treatment The drugs are chemically identical, but the legal considerations mirror the Ozempic/Wegovy distinction: Different labels and warnings Different approved uses Potential off-label prescribing Different marketing claims Case Example: Tirzepatide Injury Patient Profile: 52-year-old woman with BMI 34 No diabetes, seeking weight loss Prescribed Zepbound, escalated to 15 mg Timeline: Month 1-3: Excellent weight loss (25 lbs), manageable nausea Month 4: Persistent vomiting began Month 5: Unable to eat solid food, lost 15 more lbs Month 6: Diagnosed with severe gastroparesis via gastric emptying scan Current: 12 months post-discontinuation, still cannot eat normally, requires liquid diet Legal Claim: Inadequate warnings about permanence of gastroparesis Marketing emphasized dramatic weight loss without proper risk disclosure Failure to inform that condition might not resolve after stopping Damages include ongoing medical care, lost wages, diminished quality of life 5
These include a vegetarian bean and sweet potato shakshuka with 19g of protein and 13g of fibre
